Oxidative Stress in Human Atherothrombosis: Sources, Markers and Therapeutic Targets
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Atherothrombosis remains one of the main causes of morbidity and mortality worldwide. The underlying pathology is a chronic pathological vascular remodeling of the arterial wall involving several pathways, including oxidative stress. Cellular and animal studies have provided compelling evidence of the direct role of oxidative stress in atherothrombosis, but such a relationship is not clearly established in humans and, to date, clinical trials on the possible beneficial effects of antioxidant therapy have provided equivocal results. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is one of the main sources of reactive oxygen species (ROS) in human atherothrombosis. Moreover, leukocyte-derived myeloperoxidase (MPO) and red blood cell-derived iron could be involved in the oxidative modification of lipids/lipoproteins (LDL/HDL) in the arterial wall. Interestingly, oxidized lipoproteins, and antioxidants, have been analyzed as potential markers of oxidative stress in the plasma of patients with atherothrombosis. In this review, we will revise sources of ROS, focusing on NADPH oxidase, but also on MPO and iron. We will also discuss the impact of these oxidative systems on LDL and HDL, as well as the value of these modified lipoproteins as circulating markers of oxidative stress in atherothrombosis. We will finish by reviewing some antioxidant systems and compounds as therapeutic strategies to prevent pathological vascular remodeling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Mechanisms of plaque formation and rupture
Bentzon, J. F., Otsuka, F., Virmani, R., & Falk, E. (2014) · Circulation Research · doi:10.1161/circresaha.114.302721 · Cited by 2,391 · cited 1×
“The main feature underlying atherothrombosis is a chronic pathological remodeling of the vascular wall, characterized by lipid deposition, oxidative stress, immune-inflammatory and proliferative responses, along with proteolysis, neo-angiogenesis, apoptosis, calcification and fibrosis [1,2].”
BackgroundCellular mechanisms and physiological consequences of redox-dependent signalling
Holmström, K. M., & Finkel, T. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3801 · Cited by 2,093
The thioredoxin antioxidant system
Lu, J., & Holmgren, A. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.07.036 · Cited by 2,055 · cited 1×
“The thioredoxin (TRX) system, in which thiol-dependent peroxidases (peroxiredoxins, PRDX) are provided with electrons to remove reactive oxygen and nitrogen species rapidly, is also an important H2O2 detoxifying system [19].”
BackgroundCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943 · cited 1×
“Among functional assays measuring HDL quality, it has been shown that decreased cholesterol efflux capacity is related to incident CVD and CV events [99,100].”
BackgroundRoles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis
Förstermann, U., Xia, N., & Li, H. (2017) · Circulation Research · doi:10.1161/circresaha.116.309326 · Cited by 1,519 · cited 1×
“As mentioned above, animal models have provided important mechanistic information about the role of ROS and ROS-producing enzymes in atherothrombosis [24,25].”
BackgroundHDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390 · cited 1×
“Among functional assays measuring HDL quality, it has been shown that decreased cholesterol efflux capacity is related to incident CVD and CV events [99,100].”
BackgroundDaugherty, A., Dunn, J. L., Rateri, D. L., & Heinecke, J. W. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117342 · Cited by 1,269
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets
Drummond, G. R., Selemidis, S., Griendling, K. K., & Sobey, C. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3403 · Cited by 899 · cited 13×
“MPO is a hemoprotein mainly released by activated leukocytes that catalyzes the reaction between H2O2 and chloride ions to produce HOCl as the primary oxidant.”
BackgroundInfluentialSuperoxide Production and Expression of Nox Family Proteins in Human Atherosclerosis
Sorescu, D., Weiss, D., Lassègue, B., Clempus, R. E., Szöcs, K., Sorescu, G. P., Valppu, L., Quinn, M. T., Lambeth, J. D., Vega, J. D., et al. (2002) · Circulation · doi:10.1161/01.cir.0000012917.74432.66 · Cited by 847
Dysfunctional HDL and atherosclerotic cardiovascular disease
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.124 · Cited by 822
Presence of hypochlorite-modified proteins in human atherosclerotic lesions.
Hazell, L. J., Arnold, L., Flowers, D., Waeg, G., Malle, E., & Stocker, R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118576 · Cited by 592
Bergt, C., Pennathur, S., Fu, X., Byun, J., O'Brien, K., McDonald, T. O., Singh, P., Anantharamaiah, G. M., Chait, A., Brunzell, J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405292101 · Cited by 454
Stadler, N., Lindner, R. A., & Davies, M. J. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000124892.90999.cb · Cited by 310 · cited 1×
“Iron was observed in advanced carotid atherosclerotic plaques [58].”
BackgroundGuzik, T. J., Chen, W., Gongora, M. C., Guzik, B., Lob, H. E., Mangalat, D., Hoch, N., Dikalov, S., Rudzinski, P., Kapelak, B., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.063 · Cited by 281
Gray, S. P., Di Marco, E., Kennedy, K., Chew, P., Okabe, J., El-Osta, A., Calkin, A. C., Biessen, E. A. L., Touyz, R. M., Cooper, M. E., et al. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.307012 · Cited by 189 · cited 2×
“Another study also showed that NOX-4 mRNA levels were reduced in plaques from patients with cardiovascular events or established diabetes mellitus which was found that, together with experimental studies, pointed to a possible role of NOX-4 as a negative modulator of inflammation and remodeling to convey atheroprotect…”
BackgroundMinqin, R., Rajendran, R., Pan, N., Kwong-Huat Tan, B., Ong, W.-Y., Watt, F., & Halliwell, B. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.01.008 · Cited by 100 · cited 2×
“Treatment with the iron chelator desferrioxamine decreases lesion iron concentrations and inhibits atherosclerotic lesion development in the cholesterol-fed rabbit [151].”
BackgroundManea, A., Manea, S.-A., Gan, A. M., Constantin, A., Fenyo, I. M., Raicu, M., Muresian, H., & Simionescu, M. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.021 · Cited by 69 · cited 1×
“Finally, NOX-5 was found to be upregulated in atherosclerosis in the endothelium in the early lesions and in VSMC in the advanced coronary lesions [37] and more recently, NOX-5 was found in human monocytes and macrophages and in macrophage-rich areas within human carotid artery atherosclerotic plaques [38].”
BackgroundIto, T., Fujita, H., Tani, T., & Ohte, N. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.026 · Cited by 30 · cited 1×
“Circulating MDA-LDL levels has been proposed as a marker of oxidative stress in atherosclerotic CVD [80–82] and clinical studies have demonstrated that MDA-LDL levels are associated with the severity of coronary artery disease [83], coronary plaque vulnerability [84] and adverse clinical outcomes after percutaneous co…”
BackgroundKotani, K., Tashiro, J., Yamazaki, K., Nakamura, Y., Miyazaki, A., Bujo, H., Saito, Y., Kanno, T., & Maekawa, M. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.08.003 · Cited by 24
Cited by
The Role of Oxidative Stress in Atherosclerosis
Batty, M., Bennett, M. R., & Yu, E. (2022) · Cells · doi:10.3390/cells11233843 · Cited by 536
Perrone, A., Giovino, A., Benny, J., & Martinelli, F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3818196 · Cited by 459
Lipoxidation in cardiovascular diseases
Gianazza, E., Brioschi, M., Fernandez, A. M., & Banfi, C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101119 · Cited by 152
Silla, A., Fogacci, F., Punzo, A., Hrelia, S., Simoni, P., Caliceti, C., & Cicero, A. F. G. (2023) · Antioxidants · doi:10.3390/antiox12030578 · Cited by 25
Metadata
- Authors
- Martin-Ventura, J., Rodrigues-Diez, R., Martinez-Lopez, D., Salaices, M., Blanco-Colio, L., & Briones, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-11-03
- Volume
- 18
- Issue
- 11
- Pages
- 2315
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2765456583
- Cited by
- 69
- References
- 21
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.